test

Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

Conditions

Prostate Cancer

What is the purpose of this trial?

RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen ablation therapy may stop the adrenal glands from making androgens. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether androgen-ablation therapy is more effective with or without docetaxel in treating metastatic prostate cancer.

PURPOSE: This randomized phase III trial is studying androgen-ablation therapy and chemotherapy to see how well they work compared to androgen-ablation therapy alone in treating patients with metastatic prostate cancer.



Participation Guidelines

Age:
18 Years and older
Gender:
Male

Click here for detailed information about who can participate in this trial.


Sponsor:
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Dates:
July 2006
Last Updated:
December 4, 2012
Study HIC#:
1103008128

Clinicaltrials.gov ID: NCT00309985